Pseudomonas aeruginosa Inhibits the Growth of Cryptococcus Species

Mycopathologia

Volumn 173, Issue 5-6, 2012, Pages 451-461

  Rella, Antonella ^a,c   Yang, Mo Wei ^a   Gruber, Jordon ^a   Montagna, Maria Teresa ^c   Luberto, Chiara ^a   Zhang, Yong Mei ^a   Del Poeta, Maurizio ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

2 heptyl 3,4 dihydroxyquinoline; Cryptococcus spp.; Pseudomonas aeruginosa; Pyocyanin; Quorum sensing

Indexed keywords

PHENAZINE DERIVATIVE; PYOCYANINE; QUINOLINE; QUINOLINE DERIVATIVE;

ANTIBIOSIS; ARTICLE; BACTERIUM ADHERENCE; CHEMISTRY; CRYPTOCOCCUS; CULTURE MEDIUM; GROWTH, DEVELOPMENT AND AGING; METABOLISM; METHODOLOGY; MYCOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA;

ANTIBIOSIS; BACTERIAL ADHESION; CRYPTOCOCCUS; CULTURE MEDIA; MYCOLOGY; PHENAZINES; PSEUDOMONAS AERUGINOSA; PYOCYANINE; QUINOLINES;

ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS); CANDIDA; FILOBASIDIELLA NEOFORMANS; FUNGI; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 84860567859     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-011-9494-7     Document Type: Article

References (32)

1. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20(3): 507-544, v-vi. doi: 10. 1016/j. idc. 2006. 07. 001.
2. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature. 2005; 437(7063): 1360-4. doi: 10. 1038/nature04220.
3. Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr Opin Microbiol. 2002; 5(4): 359-65.
4. Feldmesser M, Tucker S, Casadevall A. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol. 2001; 9(6): 273-8.
5. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA, Simons ER. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun. 1999; 67(2): 885-90.
6. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis. 2002; 186(4): 522-30. doi: 10. 1086/341564.
7. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis. 2000; 19(12): 915-25.
8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1): 1-12. doi: 10. 1086/595011.
9. Gibson J, Sood A, Hogan DA. Pseudomonas aeruginosa-Candida albicans interactions: localization and fungal toxicity of a phenazine derivative. Appl Environ Microbiol. 2009; 75(2): 504-13. doi: 10. 1128/AEM. 01037-08.
10. Kerr J. Inhibition of fungal growth by Pseudomonas aeruginosa and Pseudomonas cepacia isolated from patients with cystic fibrosis. J Infect. 1994; 28(3): 305-10.
11. Kerr JR, Taylor GW, Rutman A, Hoiby N, Cole PJ, Wilson R. Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol. 1999; 52(5): 385-7.
12. Fisher AM. Inhibition of growth of Cryptococcus neoformans by cultures of Pseudomonas aeruginosa. Bull Johns Hopkins Hosp. 1954; 95(4): 157-61.
13. Teoh-Chan H, Chau PY, Ng MH, Wong PC. Inhibition of Cryptococcus neoformans by Pseudomonas aeruginosa. J Med Microbiol. 1975; 8(1): 77-81.
14. Choi JY, Sifri CD, Goumnerov BC, Rahme LG, Ausubel FM, Calderwood SB. Identification of virulence genes in a pathogenic strain of Pseudomonas aeruginosa by representational difference analysis. J Bacteriol. 2002; 184(4): 952-61.
15. Tan MW, Mahajan-Miklos S, Ausubel FM. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci USA. 1999; 96(2): 715-20.
16. Choi KH, Schweizer HP. An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol. 2005; 5: 30. doi: 10. 1186/1471-2180-5-30.
17. Tully JG Jr, Latteri A. Paraplegia, syringomyelia tarda and neuropathic arthrosis of the shoulder: a triad. Clin Orthop Relat Res. 1978; 134: 244-8.
18. Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Camara M. Quinolones: from antibiotics to autoinducers. FEMS Microbiol Rev. 2011; 35(2): 247-74. doi: 10. 1111/j. 1574-6976. 2010. 00247. x.
19. Zhang YM, Frank MW, Zhu K, Mayasundari A, Rock CO. PqsD is responsible for the synthesis of 2, 4-dihydroxyquinoline, an extracellular metabolite produced by Pseudomonas aeruginosa. J Biol Chem. 2008; 283(43): 28788-94. doi: 10. 1074/jbc. M804555200.
20. Machan ZA, Taylor GW, Pitt TL, Cole PJ, Wilson R. 2-Heptyl-4-hydroxyquinoline N-oxide, an antistaphylococcal agent produced by Pseudomonas aeruginosa. J Antimicrob Chemother. 1992; 30(5): 615-23.
21. Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S, et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett. 2010; 313(2): 96-102. doi: 10. 1111/j. 1574-6968. 2010. 02130. x.
22. Holloway BW. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol. 1955; 13(3): 572-81.
23. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science. 1995; 268(5219): 1899-902.
24. Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, Miyata S et al. Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol. 2006; 7(10): R90. doi: 10. 1186/gb-2006-7-10-r90.
25. Hogan DA, Kolter R. Pseudomonas-Candida interactions: an ecological role for virulence factors. Science. 2002; 296(5576): 2229-32. doi: 10. 1126/science. 1070784.
26. Singh A, Del Poeta M. Lipid signalling in pathogenic fungi. Cell Microbiol. 2011; 13(2): 177-85. doi: 10. 1111/j. 1462-5822. 2010. 01550. x.
27. Oliver A. Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy. Int J Med Microbiol. 2010; 300(8): 563-72. doi: 10. 1016/j. ijmm. 2010. 08. 009.
28. Hoboth C, Hoffmann R, Eichner A, Henke C, Schmoldt S, Imhof A, et al. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis. 2009; 200(1): 118-30. doi: 10. 1086/599360.
29. Bakare N, Rickerts V, Bargon J, Just-Nubling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses. 2003; 46(1-2): 19-23.
30. Hughes WT, Kim HK. Mycoflora in cystic fibrosis: some ecologic aspects of Pseudomonas aeruginosa and Candida albicans. Mycopathol Mycol Appl. 1973; 50(3): 261-9.
31. Taylor GW, Machan ZA, Mehmet S, Cole PJ, Wilson R. Rapid identification of 4-hydroxy-2-alkylquinolines produced by Pseudomonas aeruginosa using gas chromatography-electron-capture mass spectrometry. J Chromatogr B Biomed Appl. 1995; 664(2): 458-62.
32. Caldwell CC, Chen Y, Goetzmann HS, Hao Y, Borchers MT, Hassett DJ, et al. Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am J Pathol. 2009; 175(6): 2473-88. doi: 10. 2353/ajpath. 2009. 090166.